

**Exactech® Equinoxe® UHMWPE Posterior Augment Pegged Glenoids™  
Special 510(k) – 510(k) Summary of Safety and Effectiveness**

**Sponsor:** Exactech® Inc.  
2320 N.W. 66<sup>th</sup> Court  
Gainesville, FL 32653

DEC 13 2010

Phone: (352) 377-1140  
Fax: (352) 378-2617

FDA Establishment Number 1038671

**Contact:** Patrick Hughes  
Regulatory Affairs Specialist

**Date:** November 19, 2010

**Trade or Proprietary or Model Name(s):**

Exactech® Equinoxe® UHMWPE Posterior Augment Pegged Glenoids™

**Common Name:**  
Glenoid Component

**Classification Name:**  
Prosthesis, Shoulder, Semi-constrained, metal/polymer cemented (21 CFR 888.3660, Class II,  
Product Code KWS)

**Information on devices to which substantial equivalence is claimed:**

<u>510(k) Number</u>	<u>Trade or Proprietary or Model Name</u>	<u>Manufacturer</u>
K042021	Exactech Equinoxe Shoulder System	Exactech, Inc
K093430	Exactech Equinoxe Cage Glenoid, XL Keeled, & XL Pegged Glenoid	Exactech, Inc.

**Purpose of Submission:**

The modifications proposed by this submission include combining:

- the same articulating geometry and angled/augmented surface as Exactech Equinoxe Cage Glenoid, XL Keeled & XL Pegged Glenoid devices cleared via 510(k) K093430
- the same ultra high molecular weight polyethylene (UHMWPE) material and fixation features as Exactech Equinoxe Shoulder System devices cleared via 510(k) K042021

**Exactech® Equinoxe® UHMWPE Posterior Augment Pegged Glenoids™**  
**Special 510(k) – 510(k) Summary of Safety and Effectiveness**

**Indications for Use:**

The Equinoxe Shoulder System is indicated for use in skeletally mature individuals with degenerative diseases or fractures of the glenohumeral joint where total or hemi- arthroplasty is determined by the surgeon to be the preferred method of treatment.

- The cemented primary humeral stem, long/revision stem, fracture stems and all Equinoxe glenoids are intended for cemented fixation.
- The press-fit humeral stems are intended for press-fit applications but may be used with bone cement at the discretion the surgeon.
- The reverse humeral components are intended to be used in cemented applications or in revision cases when the humeral component is well-fixed/stable, as deemed by the orthopaedic surgeon.
- Humeral Heads are intended for use in cemented and press-fit applications.

Clinical indications for the PRIMARY (P), LONG/REVISION (L/R) and FRACTURE (F) humeral components are as follows:

P	L/R	F	Indications
✓	✓		rheumatoid arthritis, osteoarthritis, osteonecrosis or post-traumatic degenerative problems
✓	✓		congenital abnormalities in the skeletally mature
✓			primary and secondary necrosis of the humeral head.
✓		✓	humeral head fracture with displacement of the tuberosities
✓	✓		pathologies where arthrodesis or resectional arthroplasty of the humeral head are not acceptable
✓	✓		revisions of humeral prostheses when other treatments or devices have failed (where adequate fixation can be achieved)
		✓	displaced three-part and four-part upper humeral fractures
	✓		spiral and other fractures of the mid-humerus (in combination with glenohumeral degenerative diseases)
	✓		revision of failed previous reconstructions when distal anchorage is required
✓	✓		to restore mobility from previous procedures (e.g. previous fusion)

The Equinoxe Reverse Shoulder System is indicated for use in skeletally mature individuals with degenerative diseases of the glenohumeral joint and a grossly deficient, irreparable rotator cuff. The Equinoxe Reverse Shoulder is also indicated for a failed glenohumeral joint replacement with loss of rotator cuff function resulting in superior migration of the humeral head.

The Equinoxe Platform Fracture Stem is indicated for use in skeletally mature individuals with acute fracture of the proximal humerus and displacement of the tuberosities, displaced 3- and 4-part fractures of the proximal humerus (hemi-arthroplasty), or acute fracture of the proximal humerus with failure of the glenohumeral joint (primary total shoulder arthroplasty). The Equinoxe Platform Fracture Stem is also indicated for acute fracture of the proximal humerus in combination with degenerative diseases of the glenohumeral joint and a grossly deficient, irreparable rotator cuff resulting in superior migration of the humeral head (reverse total shoulder arthroplasty). The Equinoxe Platform Fracture Stem is indicated for cemented use only.

**Exactech® Equinoxe® UHMWPE Posterior Augment Pegged Glenoids™  
Special 510(k) – 510(k) Summary of Safety and Effectiveness**

**Device Description:**

The proposed Equinoxe UHMWPE Posterior Augment Pegged Glenoids are intended to be used with Equinoxe shoulder system components described in #K042021, #K061454, and #K093430. Equinoxe UHMWPE posterior augment glenoids combine materials and features found in the cited predicates. The proposed Equinoxe UHMWPE posterior augment glenoids are manufactured from the same materials as glenoid components cleared via #K042021 and #K093430, and feature the same articulating and angled geometry as glenoid components cleared via #K093430.

The predicate and proposed devices have the same intended use and basic fundamental scientific technology and share the following similarities:

- the same indications for use
- similar design features
- the same shelf life
- are packaged and sterilized using the same materials and processes

**Substantial Equivalence Conclusion:**

Results of mechanical testing referenced in this submission shows the proposed devices meet requirements specified in ASTM F2028, Standard Test Methods for Dynamic Evaluation of Glenoid Loosening or Disassociation and demonstrate the proposed Equinoxe UHMWPE Posterior Augment Pegged Glenoids are substantially equivalent to cited cleared predicate devices.



## DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room -WO66-G609  
Silver Spring, MD 20993-0002

Exactech, Inc.  
% Mr. Patrick Hughes  
Regulatory Affairs Specialist  
2320 Northwest 66<sup>th</sup> Court  
Gainesville, Florida 32653

DEC 13 2010

Re: K103419

Trade/Device Name: Exactech<sup>®</sup> Equinoxe<sup>®</sup> UHMWPE Posterior Augment Pegged  
Glenoids<sup>TM</sup>

Regulation Number: 21 CFR 888.3660

Regulation Name: Shoulder joint metal/polymer non-constrained cemented prosthesis

Regulatory Class: Class II

Product Code: KWS

Dated: November 19, 2010

Received: November 22, 2010

Dear Mr. Hughes:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Mark N. Melkerson  
Director  
Division of Surgical, Orthopedic,  
and Restorative Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

**Exactech® Equinoxe® UHMWPE Posterior Augment Pegged Glenoids™  
Special 510(k) – Indications for Use**

**510(k) Number:** K103419 (1/2)

DEC 13 2010

**Device Name: Exactech® Equinoxe® UHMWPE Posterior Augment Pegged Glenoids™**

The Equinoxe Shoulder System is indicated for use in skeletally mature individuals with degenerative diseases or fractures of the glenohumeral joint where total or hemi- arthroplasty is determined by the surgeon to be the preferred method of treatment.

- The cemented primary humeral stem, long/revision stem, fracture stems and all Equinoxe glenoids are intended for cemented fixation.
- The press-fit humeral stems are intended for press-fit applications but may be used with bone cement at the discretion the surgeon.
- The reverse humeral components are intended to be used in cemented applications or in revision cases when the humeral component is well-fixed/stable, as deemed by the orthopaedic surgeon.
- Humeral Heads are intended for use in cemented and press-fit applications.

Clinical indications for the PRIMARY (P), LONG/REVISION (L/R) and FRACTURE (F) humeral components are as follows:

Clinical Indication		
Primary (P)	Long/Revision (L/R)	Fracture (F)
✓	✓	
		rheumatoid arthritis, osteoarthritis, osteonecrosis or post-traumatic degenerative problems
✓	✓	
		congenital abnormalities in the skeletally mature
✓		
		primary and secondary necrosis of the humeral head.
✓		✓
		humeral head fracture with displacement of the tuberosities
✓	✓	
		pathologies where arthrodesis or resectional arthroplasty of the humeral head are not acceptable
✓	✓	
		revisions of humeral prostheses when other treatments or devices have failed (where adequate fixation can be achieved)
		✓
		displaced three-part and four-part upper humeral fractures
	✓	
		spiral and other fractures of the mid-humerus (in combination with glenohumeral degenerative diseases)
	✓	
		revision of failed previous reconstructions when distal anchorage is required
✓	✓	
		to restore mobility from previous procedures (e.g. previous fusion)

The Equinoxe Reverse Shoulder System is indicated for use in skeletally mature individuals with degenerative diseases of the glenohumeral joint and a grossly deficient, irreparable rotator cuff. The Equinoxe Reverse Shoulder is also indicated for a failed glenohumeral joint replacement with loss of rotator cuff function resulting in superior migration of the humeral head.

The Equinoxe Platform Fracture Stem is indicated for use in skeletally mature individuals with acute fracture of the proximal humerus and displacement of the tuberosities, displaced 3- and 4-part fractures of the proximal humerus (hemi-arthroplasty), or acute fracture of the proximal humerus with failure of the glenohumeral joint (primary total shoulder arthroplasty). The Equinoxe Platform Fracture Stem is also indicated for acute fracture of the proximal humerus in combination with degenerative diseases of the glenohumeral joint and a grossly deficient, irreparable rotator cuff resulting in superior migration of the humeral head (reverse total shoulder arthroplasty). The Equinoxe Platform Fracture Stem is indicated for cemented use only.

K103419 (2/2)  
IFU

**Exactech® Equinoxe® UHMWPE Posterior Augment Pegged Glenoids™**  
**Special 510(k) – Indications for Use**

**Prescription Use**   
**(Part 21 CFR 801 Subpart D)**


**and/or**

**Over-The-Counter Use**   
**(21 CFR 807 Subpart C)**

**Please do not write below this line - use another page if needed.**

---

**Concurrence of CDRH, Office of Device Evaluation (ODE)**

  
~~(Division Sign-Off)~~  
Division of Surgical, Orthopedic,  
and Restorative Devices

510(k) Number K103419